Profile data is unavailable for this security.
About the company
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.
- Revenue in USD (TTM)7.53m
- Net income in USD-6.53m
- Incorporated2007
- Employees4.00
- LocationEvoke Pharma Inc420 Stevens Avenue, Suite 230SOLANA BEACH 92075United StatesUSA
- Phone+1 (858) 345-1494
- Fax+1 (302) 636-5454
- Websitehttps://evokepharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stemtech Corp | 5.37m | -5.11m | 2.93m | 45.00 | -- | -- | -- | 0.5457 | -0.0518 | -0.0518 | 0.0529 | -0.0359 | 1.33 | 8.39 | 42.31 | -- | -126.26 | -- | -- | -- | 77.87 | -- | -95.16 | -- | 0.065 | -2.59 | -- | -- | 7.94 | -- | 36.45 | -- | -- | -- |
| Psyence Biomedical Ltd | 0.00 | 1.52m | 3.06m | -- | -- | -- | 2.02 | -- | -0.0442 | -0.0442 | 0.00 | -0.3979 | 0.00 | -- | -- | -- | 1.13 | -- | 1.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.63 | -- | -- | -- |
| NovaBay Pharmaceuticals Inc | 12.02m | -15.98m | 3.39m | 24.00 | -- | -- | -- | 0.2821 | -65.73 | -65.91 | 21.94 | -0.4577 | 1.21 | 2.29 | 7.59 | 500,958.30 | -105.75 | -61.51 | -205.52 | -83.89 | 58.55 | 59.99 | -87.67 | -86.47 | 0.4302 | -- | 8.81 | -- | 2.24 | 3.32 | -2.66 | -- | -15.46 | -- |
| China Pharma Holdings Inc | 6.25m | -4.40m | 3.43m | 231.00 | -- | 0.4636 | -- | 0.5497 | -0.6254 | -0.6254 | 0.6379 | 0.4317 | 0.417 | 2.34 | 23.57 | 27,047.32 | -29.39 | -29.66 | -59.89 | -55.25 | -25.89 | 6.47 | -70.48 | -73.09 | 0.2449 | -21.22 | 0.3494 | -- | -13.48 | -10.68 | 22.50 | -- | -25.78 | -- |
| Processa Pharmaceuticals Inc | 0.00 | -11.53m | 3.59m | 13.00 | -- | 0.9658 | -- | -- | -4.86 | -4.86 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -176.99 | -84.35 | -209.96 | -90.03 | -- | -- | -- | -- | -- | -- | 0.0022 | -- | -- | -- | 59.45 | -- | -34.05 | -- |
| Sonoma Pharmaceuticals Inc | 12.70m | -4.56m | 3.75m | 172.00 | -- | 0.5348 | -- | 0.2952 | -10.07 | -10.07 | 20.98 | 5.24 | 0.859 | 2.91 | 4.47 | 73,831.40 | -30.85 | -29.36 | -41.88 | -40.65 | 38.17 | 38.00 | -35.91 | -30.93 | 2.47 | -- | 0.0394 | -- | -4.05 | -7.66 | 6.13 | -- | -29.84 | -- |
| Titan Pharmaceuticals Inc | 4.00k | -5.46m | 3.81m | 4.00 | -- | 0.9548 | -- | 953.09 | -6.59 | -6.59 | 0.0049 | 4.37 | 0.0016 | -- | 0.1702 | 1,000.00 | -211.58 | -96.80 | -368.99 | -156.65 | -- | -- | -136,525.00 | -406.26 | -- | -309.96 | 0.00 | -- | -66.97 | -51.16 | 45.43 | -- | -65.61 | -- |
| Shuttle Pharmaceuticals Holdings Inc | 0.00 | -7.20m | 3.88m | 8.00 | -- | 3.05 | -- | -- | -10.29 | -10.29 | 0.00 | 0.3805 | 0.00 | -- | -- | 0.00 | -123.53 | -- | -147.27 | -- | -- | -- | -- | -- | -- | -4.32 | 0.5076 | -- | -- | -- | -112.71 | -- | -- | -- |
| CYANOTECH CORP | 23.82m | -5.10m | 4.14m | 77.00 | -- | 0.3878 | -- | 0.1738 | -0.7549 | -0.7549 | 3.56 | 1.53 | 0.8895 | 2.05 | 12.12 | 309,389.60 | -19.04 | -3.46 | -29.60 | -4.46 | 24.72 | 34.54 | -21.41 | -3.58 | 0.3354 | -6.61 | 0.377 | -- | -0.4616 | -5.24 | -53.11 | -- | -6.42 | -- |
| Evoke Pharma Inc | 7.53m | -6.53m | 4.15m | 4.00 | -- | 1.56 | -- | 0.5517 | -16.23 | -16.23 | 11.24 | 3.63 | 0.7128 | 0.4307 | 4.97 | 1,881,428.00 | -61.83 | -100.48 | -136.53 | -151.10 | 96.97 | -- | -86.75 | -480.52 | 1.22 | -19.91 | 0.6523 | -- | 106.51 | -- | 5.25 | -- | -- | -- |
| Tian'an Pharmaceutical Co Ltd | 10.65m | 3.14m | 4.16m | -- | 0.0232 | 0.005 | 1.14 | 0.3906 | 0.2246 | 0.2246 | 0.7611 | 1.03 | -- | -- | -- | -- | -- | -- | -- | -- | 68.54 | -- | 29.51 | -- | 13.36 | 25.66 | 0.00 | -- | 50.51 | -- | 106.71 | -- | -- | -- |
| Biofrontera Inc | 35.24m | -13.51m | 4.75m | 85.00 | -- | 0.3997 | -- | 0.1347 | -5.29 | -5.29 | 12.12 | 2.14 | 1.21 | 1.97 | 7.27 | 414,623.50 | -46.20 | -- | -113.24 | -- | 47.75 | -- | -38.33 | -- | 1.46 | -3.53 | 0.0264 | -- | 18.82 | -- | -3,045.47 | -- | -- | -- |
| Sunshine Biopharma Inc | 30.48m | -3.68m | 5.38m | 44.00 | -- | 0.1341 | -- | 0.1765 | -194.01 | -194.01 | 1,017.85 | 20.07 | 1.06 | 3.33 | 10.19 | 692,772.50 | -12.75 | -101.52 | -15.41 | -137.04 | 30.41 | 35.47 | -12.07 | -165.33 | 3.26 | -- | 0.00 | -- | 454.42 | -- | 83.15 | -- | 110.99 | -- |
| Aoxing Pharmaceutical Company Inc | 30.11m | -1.46m | 5.46m | 339.00 | -- | 0.0638 | -- | 0.1813 | -0.0192 | -0.0192 | 0.3951 | 0.2507 | 0.496 | 2.32 | 2.56 | -- | -2.41 | -14.54 | -7.06 | -35.45 | 76.19 | 68.51 | -4.85 | -37.69 | 0.7368 | 0.3387 | 0.6052 | -- | 26.88 | 37.20 | -62.49 | -- | -38.80 | -- |
Data as of Nov 08 2024. Currency figures normalised to Evoke Pharma Inc's reporting currency: US Dollar USD
34.66%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nantahala Capital Management LLCas of 06 Nov 2024 | 148.19k | 18.09% |
| Bleichroeder LPas of 30 Jun 2024 | 68.75k | 8.39% |
| Altium Capital Management LPas of 30 Jun 2024 | 57.70k | 7.04% |
| Geode Capital Management LLCas of 30 Jun 2024 | 4.14k | 0.51% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 2.49k | 0.30% |
| Citadel Securities LLCas of 30 Jun 2024 | 993.00 | 0.12% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 888.00 | 0.11% |
| Tower Research Capital LLCas of 30 Jun 2024 | 623.00 | 0.08% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 122.00 | 0.02% |
| UBS Financial Services, Inc.as of 30 Jun 2024 | 92.00 | 0.01% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
